Concepts (87)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ovarian Neoplasms | 9 | 2024 | 138 | 1.260 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2024 | 405 | 0.540 |
Why?
|
| Endometrial Neoplasms | 2 | 2013 | 55 | 0.490 |
Why?
|
| Maytansine | 2 | 2024 | 3 | 0.460 |
Why?
|
| Pelvic Organ Prolapse | 1 | 2013 | 24 | 0.420 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2013 | 93 | 0.410 |
Why?
|
| Carcinoma | 1 | 2013 | 117 | 0.400 |
Why?
|
| Thiones | 1 | 2008 | 4 | 0.310 |
Why?
|
| Chromans | 1 | 2008 | 16 | 0.310 |
Why?
|
| B7-H1 Antigen | 3 | 2023 | 53 | 0.300 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2008 | 78 | 0.290 |
Why?
|
| Folate Receptor 1 | 2 | 2024 | 3 | 0.290 |
Why?
|
| Neovascularization, Pathologic | 1 | 2008 | 138 | 0.290 |
Why?
|
| Immunoconjugates | 2 | 2024 | 84 | 0.280 |
Why?
|
| Bevacizumab | 2 | 2024 | 57 | 0.270 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2024 | 225 | 0.140 |
Why?
|
| Quality of Life | 1 | 2023 | 1140 | 0.130 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2009 | 77 | 0.120 |
Why?
|
| Female | 11 | 2024 | 31250 | 0.110 |
Why?
|
| Sterilization, Tubal | 1 | 2012 | 10 | 0.100 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2012 | 29 | 0.100 |
Why?
|
| Vaginal Smears | 1 | 2012 | 53 | 0.100 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2012 | 146 | 0.090 |
Why?
|
| Double-Blind Method | 2 | 2023 | 680 | 0.090 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2012 | 239 | 0.090 |
Why?
|
| Humans | 12 | 2024 | 60132 | 0.080 |
Why?
|
| Adenocarcinoma | 1 | 2012 | 327 | 0.080 |
Why?
|
| Early Detection of Cancer | 1 | 2012 | 272 | 0.080 |
Why?
|
| Paclitaxel | 3 | 2021 | 91 | 0.080 |
Why?
|
| Thymidine Phosphorylase | 1 | 2008 | 4 | 0.080 |
Why?
|
| Aged | 6 | 2021 | 13581 | 0.080 |
Why?
|
| Neoplasm Staging | 3 | 2021 | 460 | 0.080 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2008 | 183 | 0.070 |
Why?
|
| Aged, 80 and over | 6 | 2021 | 5197 | 0.070 |
Why?
|
| Endothelial Cells | 1 | 2008 | 177 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2008 | 807 | 0.070 |
Why?
|
| Carboplatin | 2 | 2021 | 40 | 0.060 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2008 | 483 | 0.060 |
Why?
|
| Platinum | 1 | 2024 | 21 | 0.060 |
Why?
|
| Maintenance Chemotherapy | 1 | 2024 | 12 | 0.060 |
Why?
|
| Cell Line, Tumor | 1 | 2008 | 1384 | 0.060 |
Why?
|
| Cell Proliferation | 1 | 2008 | 943 | 0.060 |
Why?
|
| Platinum Compounds | 1 | 2023 | 1 | 0.060 |
Why?
|
| Cell Line | 1 | 2008 | 2017 | 0.060 |
Why?
|
| Abdominal Pain | 1 | 2023 | 94 | 0.050 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2023 | 184 | 0.050 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2023 | 125 | 0.050 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2021 | 8 | 0.050 |
Why?
|
| Neoadjuvant Therapy | 1 | 2021 | 72 | 0.040 |
Why?
|
| Immunotherapy | 1 | 2023 | 237 | 0.040 |
Why?
|
| Genomics | 1 | 2023 | 314 | 0.040 |
Why?
|
| Biomarkers, Tumor | 1 | 2023 | 465 | 0.040 |
Why?
|
| Middle Aged | 5 | 2021 | 16535 | 0.040 |
Why?
|
| Organoplatinum Compounds | 2 | 2008 | 18 | 0.040 |
Why?
|
| Adult | 4 | 2021 | 15985 | 0.030 |
Why?
|
| Adolescent | 2 | 2021 | 5958 | 0.030 |
Why?
|
| Mutation | 1 | 2023 | 2471 | 0.030 |
Why?
|
| Mice | 1 | 2008 | 10343 | 0.030 |
Why?
|
| Oklahoma | 1 | 2012 | 6 | 0.030 |
Why?
|
| Colposcopy | 1 | 2012 | 22 | 0.030 |
Why?
|
| Retrospective Studies | 3 | 2009 | 6139 | 0.020 |
Why?
|
| Young Adult | 1 | 2021 | 4396 | 0.020 |
Why?
|
| Animals | 1 | 2008 | 19768 | 0.020 |
Why?
|
| Karnofsky Performance Status | 1 | 2009 | 12 | 0.020 |
Why?
|
| Creatinine | 1 | 2009 | 123 | 0.020 |
Why?
|
| Logistic Models | 1 | 2012 | 1259 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2008 | 61 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2009 | 281 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2008 | 233 | 0.020 |
Why?
|
| Cyclophosphamide | 1 | 2008 | 71 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2008 | 196 | 0.020 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2008 | 42 | 0.020 |
Why?
|
| Infusions, Parenteral | 1 | 2007 | 18 | 0.020 |
Why?
|
| Catheters, Indwelling | 1 | 2007 | 69 | 0.020 |
Why?
|
| Cisplatin | 1 | 2007 | 119 | 0.020 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2008 | 143 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2007 | 361 | 0.020 |
Why?
|
| Weight Loss | 1 | 2009 | 264 | 0.020 |
Why?
|
| Survival Rate | 1 | 2008 | 793 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2008 | 1066 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2012 | 2505 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2007 | 372 | 0.020 |
Why?
|
| Comorbidity | 1 | 2008 | 1098 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2012 | 2616 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2008 | 2479 | 0.010 |
Why?
|
| Risk Factors | 1 | 2012 | 5082 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2008 | 5262 | 0.010 |
Why?
|